Home » Stocks » BCTX

BriaCell Therapeutics Corp. (BCTX)

Stock Price: $3.03 USD 0.14 (4.84%)
Updated Apr 21, 2021 4:00 PM EDT - Market closed
Pre-market: $3.26 +0.23 (7.59%) Apr 22, 6:41 AM
Market Cap 20.69M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 6.70M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 21
Last Price $3.03
Previous Close $2.89
Change ($) 0.14
Change (%) 4.84%
Day's Open 2.85
Day's Range 2.84 - 3.08
Day's Volume 520,238
52-Week Range 0.00 - 3.08

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...

6 days ago - GlobeNewsWire

BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...

1 week ago - GlobeNewsWire

BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced the presentation of results from clinical studies evaluating its lead product candidate, Bria-IMT, at the American Association for Cancer Research...

1 week ago - Benzinga

Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with ...

1 week ago - GlobeNewsWire

BERKELEY, Calif. and VANCOUVER, British Columbia, March 30, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...

Other stocks mentioned: BCTXF
3 weeks ago - GlobeNewsWire

BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechn...

1 month ago - GlobeNewsWire

BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechn...

Other stocks mentioned: BCTXF
1 month ago - GlobeNewsWire

Clinical and pathological findings presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer:

Other stocks mentioned: BCTXF
2 months ago - GlobeNewsWire

BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V: BCT ) (OTCQB:BCTXF), a clinical-stage biotechnology ...

Other stocks mentioned: BCTXF
3 months ago - GlobeNewsWire

About BCTX

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics... [Read more...]

Industry
Biotechnology
Founded
2014
Stock Exchange
NASDAQ
Ticker Symbol
BCTX
Full Company Profile

Financial Performance

Financial Statements